Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alnylam Pharmaceuticals has obtained rights to RNAi delivery technology developed at the CBR Institute for Biomedical Research, a Harvard Medical School Affiliate.
Subscribe to our email newsletter
The in-licensed technology may enable small interfering RNAs – or siRNAs, the molecules that mediate RNAi – to be targeted with an engineered monoclonal antibody to tumors and other cell types, thereby broadening the scope of Alnylam’s delivery technologies for RNAi therapeutics.
“Our work in the area of RNAi demonstrates that antibody fusion proteins could potentially mediate both systemic and cell-type-specific delivery of siRNAs,” said Dr Judy Lieberman, senior investigator at CBR Institute for Biomedical Research.
In addition to this license agreement with CBR Institute, Alnylam recently entered into two relationships providing access to technologies for the systemic delivery of RNAi therapeutics.
The first agreement was with Inex Pharmaceuticals Corporation and provides access to fundamental liposome delivery technology and intellectual property for systemic RNAi therapeutics.
The second agreement was with the Massachusetts Institute of Technology (MIT), and provides access to novel liposome technology being developed in the laboratory of Professor Robert Langer.